Overview

HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

Hepatic artery infusion of oxaliplatin, leucovorin and 2400 mg/m² fluorouracil is effective in hepatocellular carcinoma. However, SILIUS study showed that sorafenib plus hepatic artery infusion of cisplatin and fluorouracil did not significantly improve overall survival compared with sorafenib alone. Whether fluorouracil is effevtive is known.

Phase:

Phase 3

Details

Lead Sponsor:

Sun Yat-sen University

Collaborators:

Guangzhou No.12 People's Hospital
Kaiping Central Hospital

Treatments:

Fluorouracil